氯诺昔康用于术后患者自控镇痛的临床疗效和安全性

目的:评价非甾体抗炎药氯诺昔康用于妇科全子宫切除术后患者自控镇痛(PCA)的疗效及安全性。方法:60例全身麻醉下行全子宫切除术术后出现中度以上疼痛的患者随机分为氯诺昔康组和吗啡组。患者根据需要启动PCA泵(氯诺昔康0.8mg/次,吗啡1mg/次,锁定时间5min)。由疼痛缓解程度(PAR)、疼痛缓解总和(TOT-PAR)和患者24h镇痛总体效果来评价镇痛效果,同时监测血小板聚集率、肝、肾功能,并观察胃肠道反应等。结果:氯诺昔康组和吗啡组的TOTPAR和镇痛总体印象评分无显著性差异(P>0.05)。吗啡组起效早于氯诺昔康 组。氯诺昔康组的恶心呕吐的发生率明显低于吗啡组。2组血小板聚集率无显著性差异(P>0.05)。结论:氯诺昔康用于妇科全子宫切除术后PCA镇痛,其镇痛效应与吗啡相近,不良反应较少。

Clinical efficacy and safety of lornoxicam used in patient-control analgesia for post-hysterectomy

Objective:To compare the efficacy and safety of lornoxicam with morphine used in patient-controlled analgesia (PCA) for post-hysterectomy. Methods: 60 post-hysterectomy patients were randomly divided into lornoxicam group and morphine group. The PCA pump (bolus injection of 0.8mg lornoxicam/5min or bolus injection of Img morphine/5min) was started according to the need of patients. The efficacy was evaluated by both PAR (pain reliefe) and TOTPAR (total pain relief). The adverse reactions were also observed. Results: No significant statistical difference in both PAR and TOTPAR as well as platelet aggregation were observed between the 2 groups, but lornoxicam has less adverse effects. Conclusion: The analgesic effect of lornoxicam used in PCA for post-hysterectomy is comparable to that of morphine but lornoxicam with less adverse effects.